Keith J. Kendall
2018
In 2018, Keith J. Kendall earned a total compensation of $8M as Chief Executive Officer at Aquestive Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $500,000 |
|---|---|
| Option Awards | $2,858,056 |
| Salary | $450,000 |
| Stock Awards | $1,792,029 |
| Other | $2,410,502 |
| Total | $8,010,587 |
Kendall received $2.9M in option awards, accounting for 36% of the total pay in 2018.
Kendall also received $500K in non-equity incentive plan, $450K in salary, $1.8M in stock awards and $2.4M in other compensation.
Rankings
In 2018, Keith J. Kendall's compensation ranked 1,016th out of 14,244 executives tracked by ExecPay. In other words, Kendall earned more than 92.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,016 out of 14,244 | 93rd |
Division Manufacturing | 338 out of 5,765 | 94th |
Major group Chemicals And Allied Products | 105 out of 2,128 | 95th |
Industry group Drugs | 81 out of 1,817 | 96th |
Industry Pharmaceutical Preparations | 56 out of 1,391 | 96th |
Source: SEC filing on April 29, 2020.
Kendall's colleagues
We found two more compensation records of executives who worked with Keith J. Kendall at Aquestive Therapeutics in 2018.